ORIGINAL PAPER



Comparing the accuracy of the new-generation intraocular lens power calculation formulae in axial myopic eyes: a meta-analysis

Hongyu Li · Zi Ye · Yu Luo · Zhaohui Li

Received: 20 December 2021 / Accepted: 15 August 2022 / Published online: 5 September 2022 $\ensuremath{\mathbb{C}}$ The Author(s) 2022

Abstract

Purpose To compare the accuracy of the new-generation intraocular lens power calculation formulae in axial myopic eyes.

Methods Four databases, PubMed, Web of Science, EMBASE and Cochrane library, were searched to select relevant studies published between Apr 11, 2011, and Apr 11, 2021. Axial myopic eyes were defined as an axial length more than 24.5 mm. There are 13 formulae to participate in the final comparison (SRK/T, Hoffer Q, Holladay I, Holladay II, Haigis for traditional formulae, Barrett Universal II, Olsen, T2, VRF, EVO, Kane, Hill-RBF, LSF for the new-generation formulae). The primary outcomes were the percentage of eyes with a refractive prediction error in $\pm 0.5D$ and $\pm 1.0D$.

Hongyu Li and Zi Ye have contributed equally to this work.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10792-022-02466-4.

H. Li · Y. Luo · Z. Li (⊠) Medical School of Chinese PLA, No. 28 Fuxing Road, Haidian District, Beijing, China e-mail: zhaohuili202104@163.com

H. Li · Z. Ye · Y. Luo · Z. Li Senior Department of Ophthalmology, The Third Medical Center of PLA General Hospital, No. 69 Yongding Road, Haidian District, Beijing 100080, China Results A total of 2273 eyes in 15 studies were enrolled in the final meta-analysis. Overall, the newgeneration formulae showed a relatively more accurate outcome in comparison with traditional formulae. The percentage of eyes with a predictive refraction error in $\pm 0.5D$ ($\pm 1.0D$) of Kane, EVO and LSF was higher than 80% (95%), which was only significantly different from Hoffer Q (all P < 0.05). Moreover, another two new-generation formulae, Barrett Universal II and Olsen, had higher percentages than SRK/T, Hoffer Q, Holladay I and Haigis for eyes with predictive refraction error in $\pm 0.5D$ and $\pm 1.0D$ (all P < 0.05). In $\pm 0.5D$ group, Hill-RBF was better than SRK/T (P=0.02), and Holladay I was better than EVO (P=0.03) and LSF (P=0.009), and Hoffer Q had a lower percentage than EVO, Kane, Hill-RBF and LSF (P=0.007, 0.004, 0.002, 0.03, respectively). Barrett Universal II was better than T2 (P=0.02), and Hill-RBF was better than SRK/T (P = 0.009). No significant difference was found in other pairwise comparison.

Conclusion The new-generation formula is more accurate in intraocular lens power calculation for axial myopic eyes in comparison with the third- or fourth-generation formula.

Keyword IOL power calculation · Cataract · Axial myopic · Meta-analysis

Introduction

Due to the increasing number of refractive errors, more and more myopia patients are now facing cataract surgery with aging. Eyes with the axial length (AL) longer than 24.5 mm usually come with axial myopia, which are also defined as moderately long or long eyes [1-3]. It is challenging for the surgeon to select appropriate intraocular lens (IOL) power calculation formulae for axial myopic eyes, especially for the highly axial myopic eyes [4, 5]. Three main sources of errors in IOL power calculation of axial myopic eyes are the AL measurement error, anterior chamber depth (ACD) measurement error and effective lens position (ELP) error [6]. With the introduction of optical biometry, the accuracy of AL and ACD measurement has been significantly improved. Now, the main source of predictive refraction error of IOL power calculation in axial myopic eyes is ELP error which is determined by IOL formulae [6].

IOL formulae have been proposed more than 40 years to calculate IOL power after cataract surgery [5]. Over the past few decades, the third- or fourthgeneration formulae (traditional formulae) still were the most common method used in IOL power calculation [7]. The third-generation formulae, including SRK/T, Hoffer Q, Holladay I, predict the postoperative ELP through the AL and corneal curvature. Earlier studies have shown that, in axial myopic eyes, SRK/T might be the most accurate formula for IOL power calculation [8]. However, some studies also suggested that the third-generation formula has no significant difference in calculating IOL power in axial myopic eyes [9, 10]. After that, the fourth-generation formulae, represented by Haigis and Holladay II, introduce other parameters, such as ACD, lens thickness and white-to-white distance, to estimate postoperative ELP and calculate IOL power. Several studies showed Haigis had a better outcome in calculating IOL power for axial myopic eyes than SRK/T, Holladay I, Holladay II and Hoffer Q formulae [11, 12]. However, consistent hyperopic errors have previously been reported in axial myopic eyes using traditional IOL power calculation formulae with ALs measured by A-scan, B-scan or optical biometry [13].

Recently, the fifth-generation formula has become available for commercial use and its performance showed promise in previous study [14]. The fifthgeneration formula is also called the new-generation formula, including the Barrett Universal II (BUII), Olsen and the other new formulae [15]. Both BUII and Olsen are based on ray-tracing method and also have been shown to be a good consistent and have a great popularity in calculating IOL power for axial myopic eyes [16]. In addition, the other formulae based on artificial intelligence (AI) were also introduced to improve the accuracy of IOL power calculation, such as Kane, Hill Radial Basis Function Calculator (Hill-RBF), Ladas Super Formula (LSF) and Pearl DGS [15]. Moreover, Emmetropia Verifying Optical (EVO), T2, VRF and Naeser formula also showed acceptable accuracy in IOL power calculation [15]. With the increasing development of the newgeneration IOL formulae, the predictive refraction error after cataract surgery has steadily decreased [15, 17]. Yet there is still considerably doubt about which formula provides the most accurate predictive refraction in axial myopic eyes. The purpose of this metaanalysis is to compare the accuracy of the new-generation formulae with traditional formulae and provide valuable clinical guidelines for choosing appropriate IOL power calculation formulae in axial myopic eyes.

Patients and methods

Study inclusion and exclusion criteria

Inclusion criteria for studies were: (1) eyes with AL longer than 24.5 mm; (2) uneventful phacoemulsification with in-bag IOL implantation; (3) at least two types of the following IOL power calculation formulae have been compared: SRK/T, Hoffer Q, Holladay I, Holladay II, Haigis, BUII, Olsen, T2, VRF, EVO, Kane, Hill-RBF, LSF; (4) biometry measurements were measured by optical biometers; (5) IOL constants were optimized; (6) postoperative refraction was performed at least two weeks for small incision surgery and 1-piece IOL implantation, more periods are needed for the others. Exclusion criteria for studies were: (1) eyes with AL shorter than 24.5 mm; (2) eyes had surgical complications or refractive surgery; (3) the percentages of eyes with refractive prediction error (PE) in $\pm 0.5D$ and $\pm 1.0D$ were unavailable. The other new formulae, Naeser 2, Panacea and Pearl-DGS, were eliminated due to the limited number of study.

Literature search

Two independent authors (H.Y.L and Y.L) searched the following databases, including PubMed, Web of Science, EMBASE and Cochrane Library. The following search terms were used in PubMed: ("lenses, intraocular" [MeSH Terms] OR "intraocular lenses"[Title/Abstract] OR "lens intraocular"[Title/ Abstract] OR "intraocular lens"[Title/Abstract] OR "IOL" [Title/Abstract] OR "IOLs"[Title/ Abstract]) AND ("calculat*"[Title/Abstract] OR "formula*"[Title/Abstract]) AND ("myopi*"[Title/ Abstract] OR "long eye" [Title/Abstract] OR "long axial length"[Title/Abstract] OR "long eyes"[Title/ Abstract] OR "long AL"[Title/Abstract] OR "long ALs"[Title/Abstract]) AND ("cohort studies"[MeSH Terms] OR "case-control studies"[MeSH Terms] OR "comparative study"[Publication Type] OR "risk factors" [MeSH Terms] OR "cohort" [Text Word] OR "compared" [Text Word] OR "groups" [Text Word] OR "case control"[Text Word] OR "multivariate"[Text Word]) AND ("last 10 years" [PDat]). After excluding the duplicate, all possible studies were reviewed ignoring the main outcomes or languages. The two authors separately evaluated the titles and abstracts and performed a manual search by searching the reference list of all the eligible studies.

Data extraction and quality assessment

The new-generation IOL power calculation formulae, including BUII, Olsen, T2, VRF, EVO, Kane, Hill-RBF and LSF, were compared with the traditional formulae including SRK/T, Hoffer Q, Holladay I, Holladay II, Haigis. PE was defined as the difference between the predictive spherical equivalent (SE) and the actually postoperative SE. The primary outcomes were the percentages of eyes with PE in $\pm 0.5D$ and \pm 1.0D. The higher of the percentages, the better of the IOL power formulae. The two authors (H.Y.L and Y.L) independently extracted the data and compared the results. Discrepancies were resolved by another author (Z.Y). A modified checklist adapted from the QUADAS-2 tool was used to assess the quality of the evidence [18, 19]. Study characteristics extracted from the eligible studies were the first author, publication year, sample size, axial length, following-up period, postoperative refraction, IOL power formulae and the percentages of eyes with PE in $\pm 0.5D$ and $\pm 1.0D$.

Statistical analysis

Pooled estimates of the odds ratio (OR) were calculated with fixed-effects model when comparing the percentage of eyes with a PE in $\pm 0.5D$ and $\pm 1.0D$ of each formula. And the results were described in forest plots, with lines representing the estimated values of different studies and their confidence intervals, and the boxes graphically representing the weight assigned to each study in calculating the combined estimator of a given outcome. Substantial heterogeneity, caused by the differences across studies rather than sampling error, was defined as I^2 value greater than 50%, and the P value for heterogeneity was less than 0.10. The random-effect model was used when heterogeneity was found. Sensitivity analysis and subgroup analysis were used to assess the change in overall effect when the I^2 value was greater than 50%. Funnel plots were used to evaluate publication bias and small-study effect. Review Manager was used to data pooling (version 5.3, Cochrane Collaboration, Oxford, UK). A possibility less than 0.05 was considered to be statistically significant.

Results

Initially, 1097 articles were identified through literature search (Fig. 1). After deleting the duplicates, 580 records remained, of which 535 records were removed because of irrelevance, such as not a clinical study, not patients without eye surgery, not comparing the accuracy of IOL formulae. Finally, 45 articles were selected for full-text assessment. Among these, five studies did not include the target formula or constant optimization, and the primary outcomes were not available in seventeen studies, and four studies evaluated eyes with axial length less than 24.5 mm, and four studies were excluded due to the other reasons, such as reviews, conference abstracts or not being an English literature. After excluding of these studies, 15 articles were used for qualitative analysis [3-5, 20-31].

Fig. 1 Flow diagram of articles selection



Study characteristics and quality assessment

A total of 2273 eyes were enrolled in 15 studies (Table 1). All eligible studies included eyes after phacoemulsification with a mono-focal IOL implanting in the capsular bag. The modified QUADAS-2 was used to quality assessment (Fig. 2). Detailed information on the comprehensive assessment is described in Appendix 1. For patient selection, only one study had inappropriate exclusions, resulting in a high risk of bias [4]. Seven studies did not clarify patient enrollment methods, resulting in an unclear risk of bias. For reference standard and flow and timing assessment, six studies performed subjective refraction and three studies did not describe the refraction method. For the index test, only two studies did not declare the definition of outcomes.

Outcomes

Among the 2273 eyes included, 115 eyes were calculated with Kane, 115 with EVO, 115 with LSF, 504 with Olsen, 1986 with BUII, 879 with Hill-RBF, 633 with T2, 1823 with Haigis, 121 with VRF, 1807 with SRK/T, 741 with Holladay II, 2131 with Holladay I and 1431 with Hoffer Q. The overall percentages of eyes with PE in $\pm 0.5D$ ($\pm 1.0D$) of the above formulae are 86.96% (99.13%), 86.09% (97.39%), 83.48% (97.39%), 77.18% (96.03%), 76.38% (96.27%), 74.74% (95.34%), 69.51% (93.21%), 67.80% (91.72%), 65.29% (91.74%), 65.08% (91.20%), 63.97% (90.28%), 59.50% (87.19%) and 54.51% (83.02%), respectively (Fig. 3).

Percentage of eyes with a PE in $\pm 0.5D$

Figure 4 shows the difference in the percentage of eves with a PE in $\pm 0.5D$ comparing BUII with the other formulae. BUII was more accurate than SRK/T (P<0.001), Hoffer Q (P<0.001), Holladay I (P < 0.001), Holladay II (P = 0.01) and Haigis (P < 0.001). Appendices 2–7 show the results of pairwise comparisons of other formulae in terms of the percentages of eyes with PE in $\pm 0.5D$. SRK/T had a significantly higher percentage of eyes with PE in $\pm 0.5D$ than Hoffer Q (P=0.009) and lower of that than Haigis, Olsen and Hill-RBF (Appendix 2, P=0.02, <0.001, =0.02, respectively). And Hoffer Q also had the lowest percentage when comparing with Haigis, Olsen, EVO, Kane, Hill-RBF and LSF (Appendix 3, P=0.02, 0.01, 0.007, 0.004, 0.002, 0.03, respectively). Additionally, significant differences were found between Holladay I and Holladay II, EVO and LSF (Appendix 4, P=0.02, 0.03 and 0.009, respectively) and between Olsen and Haigis (Appendix 6, P = 0.003).

Table 1 Ct	naracte	ristics c	of study part	ticipants													
Author/ year	Eyes	Male	Country	Mean age SD/ range	Mean AL SD/range	Follow-up (days)	Refraction method	SRK/T	ΗΟ	H	H2]	Haigis	BUII Olse	n T2	VRF EVO	Kane	RBF LSF
Kane 2016 [3]	372	NA	Australia	NA	NA	> 14	Subjective	$\mathbf{>}$	>	>	>	>	\mathbf{i}	\geq			
Kane 2016 [3]	LL	NA	Australia	NA	NA	>14	Subjective	>	>	>	>	>	\mathbf{i}	\geq			
Zhang 2016 [5]	171	87	China	57.65±12.53	29.14 ± 2.50	>30	NA	>	>	>		>	\mathbf{i}				
Doshi 2017 [21]	40	25	India	<i>5</i> 9.23 ± 11.82	24.93 ± 0.80	>28	NA	>	>	>		>					
Kane 2017 [24]	340	NA	Australia	NA	24.5–26.0	>14	Subjective			>			$\mathbf{>}$				>
Kane 2017 [24]	47	NA	Australia	NA	NA	>14	Subjective			>			$\mathbf{>}$				>
Voytsekh- ivskyy 2018 [31]	70	NA	Ukraine	NA	24.5-26.0	06	Objective	>	>	>	>	>		\geq	>		
Voytsekh- ivskyy 2018 [31]	51	NA	Ukraine	NA	NA	06	Objective	>	>	>	>	>		\geq	>		
Zhang 2018 [28]	63	30	China	64.0±7.4	31.26±1.67	30	Objective	>				>					
Idrobo 2019 [29]	63	NA	Colombia	NA	26.94 ± 1.11	> 30	NA	>		>				\geq			
Liu 2019 [<mark>23</mark>]	136	NA	China	61±11	28.85±2.02	30-90	Objective	>		>		>	$\mathbf{>}$				>
Rong 2019 [22]	79	30	China	NA	29.3±2.0	30	Objective					>	>				

(continued)	
Table 1	

Author/ year	Eyes	Male	Country	Mean age SD/ range	Mean AL SD/range	Follow-up (days)	Refraction method	SRK/T	I DH	HI I	H2]	Haigis	BUII	Olsen	I2 V	RF E	VO K	ane H	tBF LS
Wan 2019 [30]	127	NA	China	65.8 ±9.1	27.72±1.59	06	Objective	\geq	>	>		>	\geq					, F	/
Wang 2019 [20]	310	NA	America	NA	NA	>21	Objective	>	>	>		>	>	>					
Zhou 2019 [26]	98	37	China	65.23 ± 6.78	29.63±2.35	>30	Objective	>	>	>	·	>	>						
Carmona 2020 [27]	115	NA	Spain	NA	NA	90	Subjective	>	>	>	>	>	>	>		~	-	·	>
Fuest 2021 [25]	58	37	Germany	61.5 ±11.4	30.18±2.67	> 28	Subjective	>		>		>	>					٢	
Ji 2021 [4]	56	NA	China	62±9	29.11 ± 1.98	28	Subjective	\geq		>	>	>	>					۴	
AL axial leı	lgth, H	floH Q	er Q, HI H	olladay I, H2 Ho	lladay II, BUII	Barrett Univ	ersal II, RBH	7 Hill-RB	ц										



Fig. 2 Quality assessment of the eligible studies according to the modified QUADAS-2



Fig. 3 The overall percentage of refractive prediction error within ± 0.5 D and ± 1.0 D of the included formulae (HQ: Hoffer Q; H1: Holladay I; H2: Holladay I; BUII: Barrett Universal II; D: diopter)

Percentage of eyes with a PE in $\pm 1.0D$

The comparison between BUII with the others in terms of percentage of eyes with a PE in $\pm 1.0D$ is shown in Fig. 5. The percentage of eyes with a PE in $\pm 1.0D$ calculated by the BUII formula was significantly higher than the SRK/T (P < 0.001), Hoffer Q (P < 0.001), Holladay I (P < 0.001), Holladay II (P < 0.001), Holladay II (P < 0.001), Haigis (P < 0.001) and T2 (P = 0.02). Appendices 8–13 show the results of pairwise comparisons of other formulae in terms of the percentages of eyes with PE in $\pm 1.0D$. SRK/T produced a higher percentage than Hoffer Q (P = 0.006) and Haigis (P = 0.03), but a lower of that than Olsen and Hill-RBF (Appendix 8, P = 0.003 and 0.009, respectively). Additionally, Hoffer Q was less accurate than

Holladay I, Haigis and Olsen (Appendix 9, P=0.007, 0.03, 0.02, respectively). And a higher percentage of eyes with PE in $\pm 1.0D$ was also found in Olsen when comparing with Holladay I (Appendix 10, P<0.001) and Haigis (Appendix 12, P=0.002).

Heterogeneity and subgroup analysis

Forest plots showed the I^2 values, mean difference and 95% confidence interval (CI). Substantial heterogeneity was detected in 11 pairs, and then the random-effect model was used (Appendix 14–15). Sensitivity analysis indicated that I² value decreased to 0% in the comparison of the percentage of eyes with PE in ±0.5D between BUII and Holladay II by omitting Ji 2021 (Appendix 14C,

(A)	Study or Subgroup	Barrett Univ	ersal II	SRK,	T Total	Woight	Odds Ratio	Odds Ratio	
····-	Study of Subgroup	Events	TOLA	Events	Total	weight	M-H, Fixed, 93% CI		
	Carmona 2020	102	115	93	115	4.7%	1.86 [0.88, 3.89]		
	Fuest 2021	31	58	32	58	6.7%	0.93 [0.45, 1.94]		
	Ji 2021	32	56	26	56	5.0%	1.54 [0.73, 3.24]		
	Kanel 2016	285	372	248	372	25.9%	1.64 [1.19, 2.26]		
	Kane2 2016	48	77	48	77	8.1%	1.00 [0.52, 1.92]		
	Liu 2019	106	136	82	136	8.1%	2.33 [1.37, 3.96]		
	Wan 2019	110	127	105	127	6.3%	1.36 [0.68, 2.70]		
	Wang 2019	233	310	180	310	20.0%	2.19 [1.55, 3.08]		
	Zhang 2016	136	171	106	171	9.7%	2.38 [1.47, 3.86]		
	Zhou 2019	78	98	61	98	5.6%	2.37 [1.25, 4.48]		
	Total (95% CI)		1520		1520	100.0%	1 80 [1 54 2 12]		
		1161	1520	0.01	1320	100.0%	1.80 [1.54, 2.12]		
	Hetere remain Chi ²	11 52 46 0		901	20/				
	Test for overall offect:	7 - 721 (P - 2)	r = 0.24	+), I = 2.	270			'0.01 0.1 İ 1'0	100'
	Test for overall effect.	Z = 7.21 (F <	0.00001)				Favours [experimental] Favours [control]	
		Barrett Univ	ersal II	Hoffer	Q		Odds Ratio	Odds Ratio	
(B)	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI	
	Carmona 2020	102	115	82	115	13.2%	3.16 [1.56, 6,39]		
	Kane1 2016	285	372	256	372	15.6%	1.48 [1.07, 2.05]		
	Kane2 2016	48	77	41	77	13.6%	1.45 [0.76, 2.76]	i +	
	Wan 2019	110	127	93	127	13.6%	2.37 [1.24, 4.51]		
	Wang 2019	233	310	84	310	15.5%	8.14 [5.68, 11.66]	I	
	Zhang 2016	136	171	106	171	14.7%	2.38 [1.47, 3.86]		
	Zhou 2019	78	98	46	98	13.7%	4.41 [2.34, 8.29]		
			1000		1076	100.00	2 02 11 50 5 65		
	Total (95% CI)		1270		1270	100.0%	2.82 [1.59, 5.00]		
	Total events	992	FF 20 46	708		1) 12 0/	201		
	Heterogeneity: Tau ² =	0.52; Cni ⁻ = :	55.20, at 1	= 6 (P <	0.0000	$1); 1^{-} = 85$	9%	0.01 0.1 i 10	100
	Test for overall effect.	Z = 5.55 (P =	0.0004)					Favours [experimental] Favours [control]	
(C)		Barrett Univ	ersal II	Hollada	ay I		Odds Ratio	Odds Ratio	
(0)_	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% Cl	
	Carmona 2020	102	115	109	115	6.5%	0.43 [0.16, 1.18]		
	Fuest 2021	31	58	23	58	7.8%	5 45 [2 34 12 70]		
	Kane1 2016	285	372	265	372	9.6%	1.32 [0.95, 1.84]	i	
	Kane1 2017	265	340	246	340	9.6%	1.35 [0.95, 1.92]	i +	
	Kane2 2016	48	77	44	77	8.3%	1.24 [0.65, 2.37	i —	
	Kane2 2017	36	47	31	47	6.9%	1.69 [0.68, 4.18	i	
	Liu 2019	106	136	79	136	8.8%	2.55 [1.50, 4.33]]	
	Wan 2019	110	127	90	127	8.3%	2.66 [1.41, 5.04]	
	Wang 2019	233	310	105	310	9.6%	5.91 [4.17, 8.37]]	
	Zhang 2016 Zhau 2010	136	171	76	171	9.0%	4.86 [3.01, 7.84]		
	2100 2019	78	96	40	90	0.3%	4.41 [2.54, 6.29]]	
	Total (95% CI)		1907		1907	100.0%	2.28 [1.49, 3.47]	1 🔶	
	Total events	1462		1125					
	Heterogeneity: Tau ² =	0.45; $Chi^2 = 3$	80.75, df	= 11 (P <	< 0.000	$(01); I^2 = 3$	86%	0.01 0.1 1 10	100
	lest for overall effect:	Z = 3.83 (P =	0.0001)					Favours [experimental] Favours [control]	
		Barrett Unive	ersal II	Hollada	y II		Odds Ratio	Odds Ratio	
(U)	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M–H, Random, 95% Cl	
	Carmona 2020	102	115	94	115	22.2%	1.75 [0.83, 3.70]]	
	Ji 2021	32	56	10	56	19.4%	6.13 [2.58, 14.56]		
	Kanel 2016	285	372	250	372	33.6%	1.60 [1.16, 2.21]		
	Kane2 2016	48	77	44	77	24.8%	1.24 [0.65, 2.37]		
	Total (95% CI)		620		620	100.0%	1.99 [1.15, 3.43]		
	Total events	467		398				· · · · · · · · · · · · · · · · · · ·	
	Heterogeneity: $Tau^2 =$	0.20: $Chi^2 = 9$	9.48. df =	3(P = 0	.02): I ²	= 68%			
	Test for overall effect:	Z = 2.48 (P =	0.01)					0.01 0.1 I IU Favours [experimental] Favours [control]	100
		Barrett Univ	orcal II	Haid	ie		Odds Ratio	Odds Patio	
(E)	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl	
-	Carmona 2020	102	115	99	115	4.5%	1.27 [0.58, 2.77]		
	Fuest 2021	31	58	37	58	6.9%	0.65 [0.31, 1.37]		
	Ji 2021	32	56	22	56	3.8%	2.06 [0.97, 4.38]		
	Kane1 2016	285	372	255	372	23.8%	1.50 [1.09, 2.08]		
	Kane2 2016	48	77	44	77	6.6%	1.24 [0.65, 2.37]	- -	
	Liu 2019	106	136	92	136	8.1%	1.69 [0.98, 2.90]		
	Kong 2019	55	79	43	79	5.2%	1.92 [1.00, 3.68]		
	wan 2019	110	127	106	127	5.7%	1.28 [0.64, 2.56]		
	wang 2019 Zhang 2016	233	310	205	310	20.3%	1.43 [0.97, 2.20]		
	Zhang 2016 Zhou 2019	130	08	125	7/1	5 1%	2 17 [1 14 4 12]		
	254 2013	70	50	03	50	3.1%	2.17 [1.14, 4.12]		
	Total (95% CI)		1599		1599	100.0%	1.50 [1.28, 1.76]	◆	
	Total events	1216		1091					
	Heterogeneity: $Chi^2 =$	8.28, df = 10	(P = 0.60)	$(0); 1^2 = 0$	6			0.01 0.1 1 10	100
	rest for overall effect:	2 = 5.00 (P <	. 0.00001	,				Favours [experimental] Favours [control]	

Fig. 4 Forest plots of the percentage of eyes with refractive prediction error in ± 0.5 D when comparing Barrett Universal II with SRK/T (A), Hoffer Q (B), Holladay I (C), Holladay II (D), Haigis (E), Olsen (F), T2 (G), EVO (H), Kane (I), H-RBF (J), LSF (K)

P < 0.001). In addition, substantial heterogeneity was decreased to insignificant when the enrolled eyes were sub-grouped by the biometry measurement difference (IOL Master and Lenstar). The results showed that there were significant differences in comparison of the percentage of eyes



Fig. 4 (continued)

with PE in $\pm 0.5D$ (1.0D) between BUII and Hoffer Q and Holladay I in both subgroups (Appendix 14 A-B and 15 A-B, all P < 0.01). Similar results were also found when comparing SRK/T with Hoffer Q and Holladay I in $\pm 0.5D$ group and Haigis with SRK/T and Hoffer Q in $\pm 1.0D$ group (all P < 0.05). Funnel plot is shown in Appendix 16.

Discussion

The widespread application of phacoemulsification combined with in-bag IOL implantation has led to the improvement of surgical techniques and the reduction of surgical complications. Therefore, the postoperative refractive status is less affected by surgical factors

~ ~ ~	Study or Subaroup	Barrett Univ Events	ersal II Total	SRK, Events	T Total	Weight	Odds Ratio M-H. Fixed, 95% Cl	Odds Ratio M-H. Fixed, 95% Cl	
	Carmona 2020	113	115	111	115	3.5%	2.04 [0.37, 11.34]		
	Fuest 2021	47	58	44	58	15.1%	1.36 [0.56, 3.31]		
	li 2021	49	56	48	56	10.9%	1.17 [0.39, 3.47]		
	Kanel 2016	364	372	351	372	13.7%	2.72 [1.19, 6.23]		
	Kane2 2016	71	77	71	77	10.0%	1.00 [0.31, 3.25]		
	Liu 2019	132	136	118	136	6.3%	5.03 [1.66, 15.30]		
	Wan 2019	125	127	121	127	3.5%	3.10 [0.61, 15.66]		
	Wang 2019	295	310	270	310	23.7%	2.91 [1.57, 5.39]		
	Zhang 2016	166	171	160	171	8.5%	2.28 [0.78, 6.72]		
	Zhou 2019	95	98	90	98	5.0%	2.81 [0.72, 10.94]		
	Total (95% CI)		1520		1520	100.0%	2 22 [1 70 2 17]		
	Total events	1457	1520	1284	1520	100.0%	2.52 [1.70, 5.17]		
	Heterogeneity: $Chi^2 =$	763 df = 9(P = 0.57	1304					
	Test for overall effect:	Z = 5.29 (P <	0.00001)				0.01 0.1 1 10	100
								Favours [experimental] Favours [control]	
(D)		Barrett Unive	rsal II	Hoffer	Q		Odds Ratio	Odds Ratio	
(D) _	Study or Subgroup	Events	Total	Events	Total	Weight N	1-H, Random, 95% CI	M-H, Random, 95% Cl	
	Carmona 2020	113	115	113	115	7.9%	1.00 [0.14, 7.22]		
	Kanel 2016	364	372	350	372	17.0%	2.86 [1.26, 6.51]		
	Wan 2019	124	127	120	127	11.9%	2.40 [0.80, 0.70]		
	Wang 2019	295	310	186	310	19.5%	13.11 [7.44, 23.10]		
	Zhang 2016	166	171	140	171	15.6%	7.35 [2.78, 19.41]		
	Zhou 2019	95	98	75	98	13.0%	9.71 [2.81, 33.58]		
	Total (95% CI)		1270		1270	100.0%	4,59 [2.30, 9.17]		
	Total events	1228	12/0	1048					
	Heterogeneity: Tau ² =	0.56; Chi ² = 1	9.25, df =	= 6 (P =	0.004):	$I^2 = 69\%$			100
	Test for overall effect:	Z = 4.32 (P <	0.0001)					Favours [experimental] Favours [control]	100
								the second se	
(C)		Barrett Unive	rsal II	Hollada	уI		Odds Ratio	Odds Ratio	
· · · -	Study or Subgroup	Events	Total	Events	Total	Weight N	1-H, Random, 95% CI	M–H, Random, 95% Cl	
	Carmona 2020 Fuest 2021	113	58	111	58	5.0%	2.04 [0.37, 11.34]		
	Ji 2021	49	56	24	56	9.6%	9.33 [3.60, 24.19]		
	Kanel 2016	364	372	355	372	10.5%	2.18 [0.93, 5.11]		
	Kane1 2017	333	340	325	340	10.0%	2.20 [0.88, 5.45]		
	Kane2 2016 Kane2 2017	71 45	47	46	47	8.7%	1.77 [0.61, 5.13]		
	Liu 2019	132	136	129	136	7.4%	1.79 [0.51, 6.26]		
	Wan 2019	125	127	120	127	5.5%	3.65 [0.74, 17.90]		
	Wang 2019	295	310	217	310	13.0%	8.43 [4.75, 14.95]		
	Zhang 2016 Zhou 2019	166	171	142	98	9.4%	6.78 [2.56, 17.98] 8 64 [2 48 30 04]		
	21100 2015	55	50		50	7.470	0.04 [2.40, 50.04]		
	Total (95% CI)		1907		1907	100.0%	3.51 [2.21, 5.57]	◆	
	Total events	1835	4 00 df -	1651 11/B -	0.000	· 12 - E6%			
	Test for overall effect:	Z = 5.34 (P < 1)	0.00001)	- II (F =	0.009)	, 1 = 30%		0.01 0.1 1 10	100
								Favours (experimental) Favours (control)	
(D)		Bernstein Hiller terr		helloH	av II		Odds Ratio	Odds Ratio	
		Barrett Univ	ersal II	nonau					
· ´ -	Study or Subgroup	Events	ersal II Total	Events	Total	Weight	M-H, Fixed, 95% CI	M–H, Fixed, 95% Cl	
-	Study or Subgroup Carmona 2020	Events 113	ersal II <u>Total</u> 115	Events 111	Total 115	Weight 10.4%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34]	M-H, Fixed, 95% Cl	
-	Study or Subgroup Carmona 2020 Ji 2021	Events 113 49	ersal II <u>Total</u> 115 56	Events 111 31	Total 115 56	Weight 10.4% 20.8%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61]	M-H, Fixed, 95% Cl	
-	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016	Events 113 49 364	ersal II <u>Total</u> 115 56 372	Events 111 31 348	Total 115 56 372	Weight 10.4% 20.8% 40.3%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08]	M-H, Fixed, 95% Cl	
-	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Kane2 2016	Events 113 49 364 71	ersal II <u>Total</u> 115 56 372 77	Events 111 31 348 68	Total 115 56 372 77	Weight 10.4% 20.8% 40.3% 28.5%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64]	M-H, Fixed, 95% Cl	
-	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Kane2 2016 Total (95% CI)	Events 113 49 364 71	ersal II Total 115 56 372 77 620	Events 111 31 348 68	Total 115 56 372 77 620	Weight 10.4% 20.8% 40.3% 28.5%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14]	M-H, Fixed, 95% Cl	
-	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Kane2 2016 Total (95% Cl) Total events	Events 113 49 364 71 597	ersal II <u>Total</u> 115 56 372 77 620	Events 111 31 348 68	Total 115 56 372 77 620	Weight 10.4% 20.8% 40.3% 28.5% 100.0%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14]	M-H, Fixed, 95% Cl	
-	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Kane2 2016 Total (95% Cl) Total events Heterogeneity: Chi ² =	Events 113 49 364 71 597 3.28, df = 3 (ersal II <u>Total</u> 115 56 372 77 620 P = 0.35)	Events 111 31 348 68 558 $1^2 = 8\%$	Total 115 56 372 77 620	Weight 10.4% 20.8% 40.3% 28.5% 100.0%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14]	M-H, Fixed, 95% Cl	
-	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Kane2 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effects:	Events 113 49 364 71 597 3.28, df = 3 ((Z = 4.38 (P <	ersal II <u>Total</u> 115 56 372 77 620 P = 0.35) 0.0001)	Events 111 31 348 68 558 $l^2 = 8\%$	Total 115 56 372 77 620	Weight 10.4% 20.8% 40.3% 28.5% 100.0%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14]	M-H, Fixed, 95% Cl	100
	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Kane2 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect:	Events 113 49 364 71 597 3.28, df = 3 ((Z = 4.38 (P <	ersal II <u>Total</u> 115 56 372 77 620 P = 0.35) 0.0001)	Events 111 31 348 68 558 $l^2 = 8\%$	Total 115 56 372 77 620	Weight 10.4% 20.8% 40.3% 28.5% 100.0%	M-H, Fixed, 95% CI 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14]	M-H, Fixed, 95% Cl	100
(F)	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Kanel 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect:	Sarrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ	ersal II <u>Total</u> 115 56 372 77 620 P = 0.35) 0.0001) ersal II	Events 111 31 348 68 558 $1^2 = 8\%$ Haig	Total 115 56 372 77 620	Weight 10.4% 20.8% 40.3% 28.5% 100.0%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Kanel 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect:	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (I Z = 4.38 (P < Barrett Univ Events	ersal II <u>Total</u> 115 56 372 77 620 P = 0.35) 0.0001) ersal II <u>Total</u>	Events 111 31 348 68 558 1 ² = 8% Haig Events	Total 115 56 372 77 620 is Total	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Kane2 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Euert 2021	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47	ersal II <u>Total</u> 115 56 372 77 620 P = 0.35) 0.0001) ersal II <u>Total</u> 115 56 372 77 620	Events 1111 311 348 68 558 F ² = 8% Haig Events	Total 115 56 372 77 620 is Total 115 57 620	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% Cl 0.50 [0.04, 5.54] 0.50 [0.04, 5.54]	M-H, Fixed, 95% Cl	100
(E) _	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Kane2 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 ji 2021	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 49	ersal II <u>Total</u> 115 56 372 77 620 P = 0.35) 0.0001) ersal II <u>Total</u> 115 58 56	Events 111 31 348 68 558 558 558 558 112 Haig Events 114 51 43	Total 115 56 372 77 620 iis Total 115 58 56	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% Cl 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.75, 579]	M-H, Fixed, 95% Cl	100
(E) _	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Kanel 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (I Z = 4.38 (P < Barrett Univ Events 113 47 49 364	ersal II Total 1115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 58 56 372	Events 111 31 348 68 558 558 558 558 558 558 114 51 43 349	Total 115 56 372 77 620 iis Total 115 58 56 372	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% Cl 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79]	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 ji 2021 Kanel 2016 Kanel 2016	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71	ersal II 1115 56 372 77 620 P = 0.35) 0.0001) ersal II 115 58 56 372 77 620 77 620 77 620 77 620 77 620 75 63 75 63 72 77 620 75 63 75 63 75 63 75 63 77 620 75 63 75 63 75 63 77 620 75 63 75 63 75 63 77 620 75 63 75 63 75 63 75 63 75 63 75 77 620 75 63 75 63 75 77 620 75 63 75 75 75 75 63 75 77 620 75 75 75 75 75 75 75 75 75 75	Events 111 31 348 68 558 558 558 558 558 558 558	Total 115 56 372 77 620 iis Total 115 58 56 372 277	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9% 9.18	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% Cl 0.59 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64]	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Kane2 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 ji 2021 Kane1 2016 Kane2 2016 Liu 2019	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 364 71 132	ersal II Total 1115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 77 58 56 372 77 136	Events 111 31 348 68 558 558 558 558 558 558 558	Total 115 56 372 77 620 iis Total 115 58 56 372 777 136	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9% 9.1% 6.5%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% Cl 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26]	M-H, Fixed, 95% Cl	100
(E) _	Study or Subgroup Carmona 2020 ji 2021 Kane1 2016 Kane2 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kane1 2016 Kane2 2016 Liu 2019 Rong 2019	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 364 71	ersal II <u>Total</u> 115 56 372 77 620 P = 0.35) 0.0001) ersal II <u>Total</u> 115 58 56 372 77 73 6 376 77 73 75 77 77 77 77 77 77 77 77 77	Events 111 31 348 68 558 1 ² = 8% Haig Events 114 51 43 349 68 129 72	Total 115 56 372 77 620 is Total 58 58 56 372 77 136 79	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.1% 6.5% 3.1%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61]	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016 Kane2 2016 Liu 2019 Rong 2019 Wan 2019	Barrett Univ Events 113 49 364 71 32.8, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71	ersal II Total 1115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 77 136 77 136 79 227 77 136 77 77 77 77 77 77 77 77 77 7	Events 1111 348 68 558 558 558 558 558 558 558	Total 115 56 372 77 620 is Total 115 58 56 372 77 1366 79 127	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9% 9.1% 6.5% 3.4% 3.4%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% Cl 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.25, 9.21] 1.51 [0.25, 9.21]	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Kanel 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 ji 2021 Kanel 2016 Kanel 2016 Liu 2019 Rong 2019 Wang 2019 Yang 2016	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 47 364 71 32 77 364 71 132 77 125 295 166	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 77 136 79 127 131 10 10 10 10 10 10 10 10 10 1	Events 1111 311 348 68 558 558 558 558 68 12 ² = 8% Haig Events 114 43 349 68 129 72 124 273 162 127 127 127 127 127 127 127 12	is Total 115 56 372 77 620 is Total 115 58 56 372 77 136 79 127 310	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9% 9.1% 6.5% 3.1% 3.4% 22.7%	M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.25, 9.21] 2.67 [1.43, 4.97] 1.64 [0.25, 9.21] 2.67 [1.43, 4.97]	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Kanel 2016 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016 Liu 2019 Rong 2019 Wang 2019 Zhou 2019 Zhou 2019	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 166 ος	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 77 1366 79 127 3100 127 3100	Events 1111 348 68 558 12 ² = 8% Haig Events 114 51 43 349 68 129 72 124 43 349 68 129 72 124 72 127 127 127 127 147 147 147 147 147 147 147 14	is Total Total 115 56 372 77 620 is Total 158 56 372 77 136 79 127 310 127 310 127 310	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 12.9% 9.1% 6.5% 3.1% 3.4% 22.7% 8.1% 4.0%	M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.25, 9.21] 2.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 [0.40, 72, 37] 1.84 [0.61, 9.62] 1.70 [0.40, 72, 37] 1.70 [0.40, 72, 37] 1.71 [0.40, 72, 73] 1.72 [0.40, 72, 74] 1.72 [0.40, 72, 74] 1.73 [0.40, 72, 74] 1.74 [0.40, 72, 74] 1.75 [0.40, 74] 1.75 [0.4	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Garmona 2020 Ji 2021 Kanel 2016 Kane2 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016 Kane2 2016 Liu 2019 Wan 2019 Wang 2019 Zhang 2016 Zhou 2019	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (i Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 166 95	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 77 136 79 127 310 171 98	Events 1111 348 68 558 68 558 114 51 43 349 68 129 72 124 273 162 93	is Total 115 56 372 77 620 is Total 115 58 56 372 77 136 79 127 3100 171 98	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 9.2% 9.1% 6.5% 3.4% 2.5% 1.0%	M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.59 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.25, 9.21] 2.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 [0.40, 7.33]	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Kanel 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 ji 2021 Kanel 2016 Kanel 2016 Liu 2019 Rong 2019 Wang 2019 Zhou 2019 Total (95% CI)	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 364 71 364 71 132 77 125 295 166 95	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 77 136 79 127 310 171 98 159	Events 111 3148 68 558 558 1 ² = 8% Haig Events 114 51 43 349 68 129 72 124 273 162 93	is Total Total 115 56 372 77 620 is Total 115 58 56 372 77 136 372 77 136 79 127 310 171 98 1599	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9% 9.1% 3.1% 3.4% 22.7% 8.1% 4.9% 100.0%	M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.25, 9.21] 2.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 [0.40, 7.33] 1.96 [1.43, 2.69]	M-H, Fixed, 95% Cl	100
(E) _	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Kanel 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016 Liu 2019 Rong 2019 Wang 2019 Zhang 2016 Zhong 2019 Total (95% CI) Total (95% CI) Total (95% CI)	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 166 95 1534	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 77 1366 79 127 3100 171 98 1599	Events 1111 3148 68 558 1 ² = 8% Haig Events 114 51 43 349 68 129 68 124 273 162 93 1478	is Total 115 56 372 77 620 is Total 115 58 56 372 77 136 79 127 310 171 98 1599	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 12.9% 9.1% 6.5% 3.1% 3.4% 22.7% 8.1% 4.9% 100.0%	M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.25, 9.21] 2.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 [0.40, 7.33] 1.96 [1.43, 2.69]	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016 Kane2 2016 Liu 2019 Wang 2019 Wang 2019 Wang 2019 Zhang 2016 Zhou 2019 Total (95% CI) Total events Heterogeneity: Chi ² =	Barrett Univ Events 113 49 364 71 328, df = 3 (i Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 Exerts 113 47 49 364 71 125 295 166 95 1534 9.48, df = 10	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 77 136 79 127 3100 1711 98 1599 (P = 0.45)	Events 111 31 348 68 558 $ ^2 = 8\%$ Haig Events 114 51 43 349 68 129 72 124 273 162 93 1478 80); ^2 = 0	is Total 115 56 620 620 620 58 77 620 115 58 63 72 77 136 372 77 136 372 77 136 372 77 136 372 77 136 372 77 56 620 56 56 56 56 620 56 56 56 56 56 56 57 57 57 57 57 57 57 57 57 57	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 9.2% 9.1% 6.5% 3.4% 22.7% 8.1% 4.9% 100.0%	 M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.57 [0.53, 4.64] 1.51 [0.25, 9.21] 2.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 [0.40, 7.33] 1.96 [1.43, 2.69] 	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Kanel 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Kanel 2016 Kanel 2016 Liu 2019 Rong 2019 Wang 2019 Zhou 2019 Total (95% CI) Total events Heterogeneity: Chi ² = Error overall effect:	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 47 113 47 364 71 132 77 125 295 166 95 1534 9.48, df = 10 Z = 4.21 (P <	ersal II Total 1155 56 372 77 620 P = 0.35) 0.0001) ersal II Total 1155 58 58 58 372 77 1366 372 77 130 127 310 127 310 (P = 0.45 0.0001) (P = 0.0001) (P = 0.0001) (P = 0.0001)	Events 111 31 348 68 558 Haig Events 114 51 43 349 68 129 72 124 4273 162 93 1478 9); $l^2 = 0$	Total 115 56 372 77 620 iss Total 115 58 56 372 77 620 iss Total 115 58 56 372 77 136 79 127 310 171 98 1599 %	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9% 9.2% 3.1% 3.4% 4.9% 100.0%	 M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.25, 9.21] 2.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 (0.40, 7.33] 1.96 [1.43, 2.69] 	M-H, Fixed, 95% Cl	100
(E)	Study or Subgroup Carmona 2020 JI 2021 Kanel 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 JI 2021 Kanel 2016 Kanel 2016 Kanel 2016 Kanel 2016 Kanel 2016 Zhou 2019 Wang 2019 Zhang 2019 Zhang 2019 Zhang 2019 Zhang 2019 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect:	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 166 95 95 95 95 95 1534 9.48, df = 10 Z = 4.21 (P < Barrett Univ Barrett Univ Events 167 168 168 168 168 168 168 168 168	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 155 58 56 372 77 1366 79 127 3100 171 98 1599 (P = 0.45 0.0001) 98 1599	Events 1111 3148 68 558 Haig Events 114 51 43 3499 68 129 72 124 273 162 93 1478 b); $l^2 = 0$	 Total Total 115 56 372 77 620 620 is Total 115 58 56 372 77 620 63 72 77 73 73 73 73 74 75 75 76 76 76 76 77 77 620 63 72 77 77 620 77 620 77 620 76 76 77 76 76 77 77 78 79 78 79 79 70 70 71 70 71 70 71 71 72 73 74 75 76 76 76 77 76 76 76 77 76 77 76 77 76 76 77 76 77 76 77 76 77 76 77 76 77 76 76 76 77 76 76 77 76 77 76 76 77 76 76 76 76 76 76 76 76 <	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 12.9% 9.1% 6.5% 3.1% 3.4% 22.7% 8.1% 4.9% 100.0%	M-H, Fixed, 95% CI 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% CI 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.25, 9.21] 1.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 [0.40, 7.33] 1.96 [1.43, 2.69]	M-H, Fixed, 95% Cl 0.01 0.1 1 10 Favours [experimental] Favours [control] Odds Ratio M-H, Fixed, 95% Cl 0.01 0.1 1 10 Favours [experimental] Favours [control] 0.01 0.1 1 10 Favours [experimental] Favours [control]	100
(E) (F)	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016 Kane2 2016 Liu 2019 Wang 2019 Wang 2019 Wang 2019 Zhang 2016 Zhou 2019 Total events Heterogeneity: Chi ² = Test for overall effect:	Barrett Univ 597 3.28, df = 3 (Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 166 95 1534 9.48, df = 10 Z = 4.21 (P < Barrett Univ Events	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 77 136 79 127 3100 171 98 1599 (P = 0.45 0.0001) ersal II 79 10 10 10 171 10 10 10 10 10 10 10 10 10 1	Events 111 31 348 68 558 68 558 68 68 68 12 8 144 51 43 349 68 129 72 72 124 273 162 93 1478 0; 1 ² = 0 0 Sc Part 10 0 1478 0 1478 0 1478 0 1478 0 1478 0 1478 0 1478 0 1478 0 1478 0 1478 0 1478 0 1478 0 1478 0 1478 0 1478 0 14788 1478 147888 147888 147888 147888 1478888 1478888 1478888 1478888 14788888 147888	Total 115 566 372 77 620 is Total 115 566 77 620 is Total 115 566 572 777 1366 372 777 1363 372 777 1366 372 777 1366 372 777 1363 372 777 1363 777 1363 777 1364 777 1370 771 138 1599 % m 707 139	Weight 10.4% 20.8% 20.8% 20.8% 100.0% Weight 3.4% 9.2% 9.1% 6.5% 3.4% 22.7% 8.1% 4.9% 100.0%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% Cl 0.59 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.57 [0.53, 4.64] 0.59 [0.04, 5.54] 0.64 [0.5, 562] 1.70 [0.40, 7.33] 1.96 [1.43, 2.69] Odds Ratio M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl	100
(E) (F)	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Kane2 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kane1 2016 Kane2 2016 Liu 2019 Rong 2019 Wang 2019 Zhang 2019 Zhang 2016 Zhou 2019 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 166 95 1534 9.48, df = 10 Z = 4.21 (P < Barrett Univ Events 13 15 15 15 15 15 15 15 15 15 15	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II 115 58 58 372 77 136 372 77 136 79 127 310 171 98 1599 (P = 0.45 0.0001) ersal II Total 127 77 127 79 127 71 128 129 127 127 129 127 129 127 127 129 127 129 127 129 127 129 127 129 127 129 129 127 129 129 129 129 129 129 129 129	Events 111 31 348 68 558 F ² = 8% Haig Events 114 51 43 349 72 124 43 349 72 124 43 349 72 124 273 162 93 1478 80 05 114 129 93 1478 114 129 127 127 127 127 127 127 127 127	Total Total 1155 56 372 77 620 620 620 620 79 9 8 558 6 372 77 77 7136 620 115 58 6 372 77 77 7136 115 58 6 372 77 77 620 8 8 6 6 372 77 77 620 8 8 6 6 372 77 77 620 8 8 6 6 6 72 77 77 620 8 8 72 77 77 77 620 8 8 72 77 77 77 77 620 8 8 72 77 77 77 77 77 77 77 77 77 77 77 77	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9% 9.2% 12.9% 9.2% 12.9% 9.2% 100.0%	M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.57 [0.53, 4.64] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.25, 9.21] 2.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 [0.40, 7.33] 1.96 [1.43, 2.69] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54]	M-H, Fixed, 95% Cl	100
(E) (F)	Study or Subgroup Carmona 2020 ji 2021 Kanel 2016 Kane2 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016 Liu 2019 Rong 2019 Wang 2019 Wang 2019 Wang 2019 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Rong 2019	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 166 95 95 1534 948, df = 10 Z = 4.21 (P < Barrett Univ Events 113 77 77 77	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II 115 58 56 372 77 1366 372 79 127 3100 171 98 1599 (P = 0.45 0.0001) ersal II 79 (P = 0.45 0.0001) ersal II 115 58 56 58 56 58 56 58 56 58 56 58 58 56 58 58 56 58 58 56 58 58 56 58 58 56 58 58 58 58 58 58 58 58 58 58	Events 1111 313 348 68 558 12 = 8% Haig Events 114 51 43 349 68 129 72 1273 162 93 1478 0156 Events 114 75 0156 Events	Total Total 115 56 372 77 620 620 63 77 77 620 63 77 77 136 372 77 7310 115 58 6 372 77 7310 117 136 372 79 7310 127 310 127 310 127 310 127 73 73 73 73 73 73 73 73 73 73 73 73 73	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9% 9.1% 6.5% 3.4% 12.9% 9.1% 6.5% 3.4% 12.9% 9.1% 6.5% 9.1% 6.5% 9.1% 6.5% 9.1% 6.5% 9.1% 6.5% 9.1% 6.5% 9.1% 6.5% 9.1% 6.5% 9.1% 6.5% 9.1% 100.0% 10.5%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% Cl 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.52, 9.21] 2.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 [0.40, 7.33] 1.96 [1.43, 2.69] Odds Ratio M-H, Fixed, 95% Cl 0.50 [0.04, 5.54] 2.05 [0.37, 11.55]	M-H, Fixed, 95% Cl	100
(E) (F)	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Kane2 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016 Kane2 2016 Liu 2019 Wan 2019 Wan 2019 Zhang 2016 Zhou 2019 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Rong 2019 Carmona 2020 Rong 2019 Carmona 2020 Rong 2019	Barrett Univ 597 3.28, df = 3 (Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 166 95 95 1534 9.48, df = 10 Z = 4.21 (P < Barrett Univ Events 113 77 295	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 77 1360 79 127 3100 171 98 1599 (P = 0.45 0.0001) ersal II (P = 0.45 0.0001) ersal II 115 79 3100 157 79 3100 157 79 3100 157 79 3100 157 79 3100 157 79 157 70 70 70 70 70 70 70 70 70 7	Events 111 313 348 68 558 $ 1^2 = 8\%$ Haig Events 114 51 43 349 68 129 72 124 273 162 93 1478 0); $ 1^2 = 0$ Olsse Events 114 75 295	Total Total 1155 56 372 77 620 620 620 77 620 77 620 77 85 85 85 85 85 85 87 9 9127 71 98 1599 % % 79 9310	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 9.2% 9.1% 6.5% 3.1% 2.5% 100.0% Weight 1.4% 1.00.0% Weight 100.0% Weight 10.9% 10.5% 78.6%	M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.59 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.57 [0.53, 4.64] 0.59 [0.04, 5.54] 2.05 [0.37, 11.55] 1.00 [0.48, 2.08]	M-H, Fixed, 95% Cl	100
(E) (F)	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016 Kane2 2016 Liu 2019 Rong 2019 Wang 2019 Zhang 2016 Zhou 2019 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Rong 2019	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 1534 9.48, df = 10 Z = 4.21 (P < Barrett Univ Events 113 77 295	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II 115 58 56 372 77 136 372 77 136 79 127 310 171 98 159 (P = 0.45 0.0001) ersal II Total 115 58 58 58 58 58 58 58 58 58 5	Events 111 31 348 68 558 68 Events 114 51 43 349 68 68 114 51 43 349 68 68 114 51 43 349 68 68 114 51 43 349 68 68 114 51 51 68 114 51 51 68 114 51 51 68 114 51 51 68 114 51 51 68 114 51 51 68 114 51 51 68 114 51 51 68 114 51 51 68 114 51 51 68 114 51 51 68 114 51 51 68 114 51 51 68 114 51 51 68 68 114 51 51 68 68 114 51 51 68 68 114 51 51 68 68 114 51 51 68 68 114 51 51 68 68 68 114 51 51 68 68 68 68 68 68 68 68 68 68	Total Total 1155 56 372 77 620 620 620 620 79 927 7136 372 77 136 372 77 136 372 77 136 372 77 136 372 77 136 372 115 58 6 372 77 77 620 620 620 83 72 77 77 620 620 85 66 372 77 77 620 620 85 66 372 77 77 620 85 66 372 77 77 620 620 85 66 372 77 77 620 85 66 372 77 77 620 85 66 372 77 77 77 77 77 77 77 620 85 66 372 77 77 77 77 77 77 77 77 77 77 77 77 7	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9% 9.2% 12.9% 9.2% 12.9% 9.2% 12.9% 9.2% 12.9% 9.2% 12.9% 9.2% 100.0% Weight 10.9% 10.5% 78.6%	M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.25, 9.21] 2.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 [0.40, 7.33] 1.96 [1.43, 2.69] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54] 2.05 [0.37, 11.55] 1.00 [0.48, 2.08]	M-H, Fixed, 95% Cl	100
(E) (F)	Study or Subgroup Ji 2021 Kanel 2016 Kane2 2016 Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Jj 2021 Kanel 2016 Liu 2019 Rong 2019 Wang 2019 Wang 2019 Wang 2019 Total (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Carmona 2020 C	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (l Z = 4.38 ($P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 166 95 1534 9.48, df = 10 Z = 4.21 (P < Barrett Univ Events 113 77 295 165 95 166 95 167 177 125 295 168 177 125 295 166 95 1534 95 167 177 125 295 166 95 1534 177 125 295 166 95 1534 177 175 177 175 175 177 175 175$	ersal II Total 1155 56 372 77 620 P = 0.35) 0.0001) ersal II 1155 58 56 372 77 1366 372 79 127 136 98 1599 (P = 0.45 0.0001) 98 1599 (P = 0.45 0.0001) 98 1599 27 310 579 310 579 310 504	Events 111 31 348 68 558 12 = 8% Haig Events 114 51 43 349 68 129 72 124 43 349 68 129 72 124 43 349 68 12 = 8% Haig Events 114 51 43 349 68 12 = 8% Haig Events 114 51 43 349 68 12 = 8% 114 51 43 349 68 12 = 8% 114 51 43 349 68 12 = 8% 114 51 43 349 68 12 = 8% 114 51 43 349 68 12 = 12 144 51 43 349 68 12 = 12 124 144 273 162 93 147 147 162 93 147 162 93 147 162 93 147 162 93 147 162 93 147 162 93 147 162 93 147 162 93 147 162 93 147 162 93 114 175 162 93 114 175 162 93 114 175 162 93 114 175 162 93 114 175 162 93 162 164 175 162 163 162 164 175 164 165 165 165 165 165 165 165 165	1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9% 9.1% 6.5% 3.4% 12.9% 9.2% 12.9% 9.1% 6.5% 3.4% 12.9% 9.1% 6.5% 3.4% 12.9% 9.1% 6.5% 3.4% 100.0% Weight 100.5% 78.6% 100.0%	M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.75, 78] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.55, 9.21] 2.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 [0.40, 7.33] 1.96 [1.43, 2.69] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54] 2.05 [0.37, 11.55] 1.00 [0.48, 2.08] 1.06 [0.56, 2.00]	M-H, Fixed, 95% Cl	100
(E) (F)	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Kane2 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016 Kane2 2016 Liu 2019 Wan 2019 Wang 2019 Zhang 2016 Zhou 2019 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Rong 2019 Wang 2019 Total (95% CI) Total events Heterogeneity: Chi ² = Total (95% CI) Total events Heterogeneity: Chi ² =	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 166 364 71 132 77 125 295 168 168 95 95 1534 95 95 1534 95 95 1534 95 95 168 167 177 175 175 175 167 175 175 167 175 175 175 175 175 175 175 17	ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 155 58 56 372 77 1366 79 127 3100 171 98 1599 (P = 0.45 0.0001) ersal II Total 155 58 56 79 136 79 136 79 137 3100 171 79 137 3100 57 79 136 79 137 3100 171 79 136 79 137 3100 171 79 127 3100 171 79 127 3100 171 79 127 3100 171 79 127 3100 171 79 127 3100 171 79 127 3100 171 79 127 3100 171 79 127 3100 171 79 127 3100 171 79 127 3100 171 79 127 3100 171 79 127 3100 171 79 1599 8 7 7 7 7 7 7 7 7 7 7 7 7 7	Events 1111 3148 68 558 $ ^2 = 8^{3}$ Haig Events 114 51 43 349 68 129 68 124 273 162 93 1478 93 1478 01sc Events 114 75 295 484 $ ^2 = 8^{3}$	7.7 Total Total 115 56 6 372 77 620 620 6 6 77 77 136 6 372 77 73 10 115 58 8 58 8 58 6 372 77 73 10 117 136 79 127 70 136 79 127 70 136 79 127 70 136 79 79 127 70 136 79 79 127 70 136 79 79 127 70 136 79 79 127 70 136 79 79 127 70 136 79 79 79 79 79 79 79 79 70 70 70 70 70 70 70 70 70 70 70 70 70	Weight 10.4% 20.8% 40.3% 28.5% 100.0% Weight 3.4% 16.6% 9.2% 12.9% 9.1% 6.5% 3.1% 3.1% 3.1% 3.1% 3.1% 3.1% 100.0% Weight 10.5% 10.5% 100.6%	M-H, Fixed, 95% Cl 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% Cl 0.50 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.79 [0.51, 6.26] 3.74 [0.75, 18.61] 1.51 [0.25, 9.21] 2.67 [1.43, 4.97] 1.84 [0.61, 5.62] 1.70 [0.40, 7.33] 1.96 [1.43, 2.69] Odds Ratio M-H, Fixed, 95% Cl 0.50 [0.04, 5.54] 2.05 [0.37, 11.55] 1.00 [0.48, 2.00]	M-H, Fixed, 95% Cl	100
(E) (F)	Study or Subgroup Carmona 2020 Ji 2021 Kanel 2016 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Fuest 2021 Ji 2021 Kanel 2016 Liu 2019 Wan 2019 Wan 2019 Wan 2019 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Carmona 2020 Rong 2019 Total events Heterogeneity: Chi ² = Total (95% CI)	Barrett Univ Events 113 49 364 71 597 3.28, df = 3 (Z = 4.38 (P < Barrett Univ Events 113 47 49 364 71 132 77 125 295 1534 9.48, df = 10 Z = 4.21 (P < Barrett Univ Events 113 77 295 295 0.97, df = 2 (Z = 0.16 (P = 2) Z = 0.16 (P = 2) 200 (P = 2) (Z = 0.16 (P = 2) (ersal II Total 115 56 372 77 620 P = 0.35) 0.0001) ersal II Total 115 58 56 372 77 1360 79 127 3100 171 98 1599 (P = 0.45 0.0001) ersal II Total 115 79 3100 504 P = 0.62) 0.87)	Events 111 31 348 68 558 68 558 68 68 68 68 68 12 8 147 68 129 72 124 273 162 93 1478 93 1478 93 1478 93 1478 93 1478 93 1478 93 1478 93 1478 93 1478 93 1478 1478 93 1478 93 14788 1478 1478 14788 14788 14788 14788 14788 1	Total Total 115 56 372 77 620 115 58 6 372 77 620 115 58 6 372 77 136 79 127 310 171 98 1599 % * * * * * * * * * * * * * * * * * *	Weight 10.4% 20.8% 20.8% 20.8% 20.8% 20.8% 20.8% 100.0% Weight 3.4% 106.5% 3.1% 3.4% 22.9% 9.2% 12.9% 9.2% 12.9% 9.2% 12.9% 9.2% 12.9% 9.2% 12.9% 9.2% 100.0% Weight 10.9% 10.5% 78.6% 100.0%	M-H, Fixed, 95% C1 2.04 [0.37, 11.34] 5.65 [2.18, 14.61] 3.14 [1.39, 7.08] 1.57 [0.53, 4.64] 3.10 [1.87, 5.14] Odds Ratio M-H, Fixed, 95% C1 0.59 [0.04, 5.54] 0.59 [0.21, 1.64] 2.12 [0.77, 5.79] 3.00 [1.32, 6.79] 1.57 [0.53, 4.64] 1.57 [0.53, 4.64] 0.59 [0.41, 5.62] 1.70 [0.40, 7.33] 1.96 [1.43, 2.69] Odds Ratio M-H, Fixed, 95% C1 0.50 [0.04, 5.54] 2.05 [0.37, 11.55] 1.00 [0.48, 2.08] 1.06 [0.56, 2.00]	M-H, Fixed, 95% Cl	100

Fig. 5 Forest plots of the percentage of eyes with refractive prediction error in \pm 1.0 D when comparing Barrett Universal II with SRK/T (A), Hoffer Q (B), Holladay I (C), Holladay II (D), Haigis (E), Olsen (F), T2 (G), EVO (H), Kane (I), H-RBF (J), LSF (K)



Test for overall effect: Z = 0.45 (P = 0.65)

Fig. 5 (continued)

than it was in the past. Yet the utmost importance that affects the refractive status after cataract surgery is the accuracy of IOL power calculation which is closely related to the choice of IOL formula. A previous meta-analysis by Wang et al. compared the accuracy of different IOL formulae in axial myopic eyes and demonstrated the superiority of BUII over SRK/T, Hoffer Q, Holladay I and Holladay II [32]. However, they did not compare the newest formulae based on ray tracing or AI methods.

Previous studies indicated that several measures could be used to evaluate the accuracy of IOL formulae, such as MAE, median absolute prediction error (MedAE), as well as the percentage of eyes with PE in $\pm 0.5D$ and $\pm 1.0D$ and > 2.00D [33]. It is better to compare MedAE and MAE when comparing the accuracy of different IOL power calculation formulae. However, both MedAE and MAE are abnormal Gaussian distribution and it is also difficult to obtain standard deviation values, resulting in the impossibility to compare the MedAE and MAE in this meta-analysis. Therefore, we choose to compare the percentage of eyes with PE in $\pm 0.5D$ and $\pm 1.0D$. In addition, as the central cornea alter to the flattest area after myopic ablation, the ratio between anterior and posterior corneal curvature would decrease [34]. This meta-analysis excluded myopic eyes with previous refractive surgery because of the corneal power measurement error and ELP error after laser ablation [35, 36]. Moreover, in the present study, we included studies that used the optical biometer (IOL Master or Lenstar) for biometry measurements, which was recommended as the best precision of measurements

Favours [experimental] Favours [control]

[33]. Postoperative refraction should be measured at least 2 weeks, because it could be considered to be stable at 1 week after small incision cataract surgery with a 1-piece IOL implantation [37, 38]. In order to control heterogeneity and biasness, we also excluded the studies which did not perform the constant optimization procedure. Additionally, the newgeneration IOL formulae (BUII, Olsen, T2, VRF, EVO, Kane, Hill-RBF and LSF) were compared with traditional ones (SRK/T, Hoffer Q, Holladay I, Holladay II, Haigis). To our knowledge, this is the first meta-analysis to assess the accuracy of the new-generation IOL power calculation formulae in axial myopic eyes by comparing the percentage of eyes with PE in $\pm 0.5D$ and $\pm 1.0D$.

Traditionally, IOL power calculation formulae were classified by generation. For example, SRK II is a second-generation formula; SRK/T, Hoffer Q and Holladay I are third-generation formulae; Holladay II and Haigis are fourth generation; Barrett Universal II, Olsen and another new formula are fifth generation, which also called the new generation. Over the past four decades, cataract surgeons usually applied the third- or fourth-generation formulae to calculate the IOL power in virgin eyes. Previous studies showed that, for axial myopic eyes, SRK/T was slightly better than Hoffer Q and Holladay I [39-41]. Similar results were found in this meta-analysis. However, all third-generation formulae showed a lower percentage of eyes with PE in $\pm 0.5D$ and $\pm 1.0D$ than Haigis. The disadvantage of third-generation formulae is that only two variables (AL and corneal power) are used to determine the postoperative IOL position, making it inaccurate to evaluate the actual size of the anterior segment of the eyes. The Haigis formula adds ACD and the Holladay II adds ACD, lens thick, corneal diameter, pre-refraction and gender to calculate the postoperative IOL position [42]. Although the fourthgeneration formulae introduce more parameters to estimate the ELP, most traditional formulae could make a hyperopic drift postoperatively, and even the longer the axial length is, the higher the PE is made. It might be associated with a slight but significant reduction in the AL measurement after cataract surgery. Maddalena et al. pointed out two hypotheses to expound the differences in AL measurement, including the decrease in the volume of the eye postoperatively and the wrong refractive index of the lens due to the cataract grade preoperatively [43].

In order to improve the accuracy of IOL power calculation, it has recently come up with several new formulae, collectively called the fifth-generation formulae, such as BUII, Olsen and formulae based on AI [15]. Each of these formulae uses at least five variables to calculate IOL position. The BUII is the evolution of the Barrett Universal I, published as a thicklens paraxial formula [44]. Kane et al. have proved that BUII is the most accurate formula in comparison with the third- and fourth- generation formulae for IOL power calculation in medium, medium-long and long eyes [3]. It showed a higher percentage of eves with PE in $\pm 0.5D$ and a lower MAE as well as MedAE. In our meta-analysis, BUII also showed a higher percentage of eyes with PE in $\pm 0.5D$ and $\pm 1.0D$ than SRK/T, Hoffer Q, Holladay I, Holladay II and Haigis. In addition, our study included Olsen formula which is based on ray-tracing method and uses a special C-constant to estimate ELP [45]. C-constant is based on ACD, lens thickness and IOL constant, and no longer dependent on AL or corneal power. Meanwhile, it also considers corneal irregularity, pupil diameter and IOL thickness to minimize the aberration. Melles and Rong demonstrated its superiority for IOL power calculation in comparison with traditional formulae [16, 22]. Our meta-analysis also found the accuracy of Olsen could be comparable to BUII, which is significantly better than the third- and fourth-generation formulae.

Except for all above-mentioned formulae, there are a lot of the other new formulae being proposed to calculate IOL power, where T2 is a modification of the original SRK/T, and VRF or EVO is a vergence formula even it is unpublished, as well as several formulae based on AI, such as Kane, Hill-RBF and LSF [15, 46]. Although all these formulae were reported high accuracy, they have been tested by a few studies [30, 31]. Hill-RBF is the first AI formula installed on the Lenstar, which uses pattern recognition and data interpolation to calculate the IOL power; Kane is a new formula based on theoretical optics and contains some element of AI, but its structure is largely unknown; LSF uses the postoperative data of more than 4000 eyes to build a three-dimensional model to calculate IOL power [24, 30, 47]. It recently was reported that EVO and Hill-RBF had a more popularity and excellent outcome in IOL power calculation for axial myopic eyes [30]. In this meta-analysis, we found that Hill-RBF had a significantly higher percentage of eyes with PE in $\pm 0.5D$ and $\pm 1.0D$ than SRK/T. No statistical difference was found between the other new formulae and traditional formulae. Interestingly, our study indicated that Kane, EVO and LSF showed a higher percentage of eyes with PE in $\pm 0.5D$ and $\pm 1.0D$ than the others, even without statistically significant differences. The possible reason might be that all three formulae are created with "big data" techniques and using several basic parameters to make its predictions [48, 49]. Due to the limit number of the enrolled eyes with VRF, EVO, LSF and Kane, it is still difficult to determine which new formulae are the most accurate one for IOL power calculation in axial myopic eyes.

This meta-analysis has several limitations. Firstly, a few of the enrolled studies were retrospective settings with a small sample size, which could cause a selective bias that is relative to the variability of patient characteristics, multiple IOL types and a single-center study. However, it is considered acceptably to compare the accuracy of IOL power calculation formulae [50]. Second, although the AL of all included eyes was longer than 24.5 mm, the scope of AL was different between different studies. This would have a small effect on the eventual results. Next, one of the enrolled study might include both eyes of the same patient, which could lead smaller P-values [23]. But there were only 136 eyes of 92 patients in this study. It might not significantly affect the final results of 2273 eyes. Finally, only one study included the EVO, Kane and LSF. Therefore, the results in comparison with these three formulae have a limited application. Future studies need to investigate the accuracy of these results for IOL power calculation in axial myopic eyes.

Conclusions

This meta-analysis reveals promising results for the new-generation formula, such as Kane, EVO, LSF, BUII and Hill-RBF, in IOL power calculation for axial myopic eyes. These new formulae have a higher percentage of eyes with a PE both in ± 0.5 D and ± 1.0 D than traditional formulae, such as SRK/T, Hoffer Q, Holladay I/II and Haigis.

Authors' contributions HYL, ZY designed the study and drafted the manuscript; ZHL conducted the study; HYL, YL

helped in data collection, analysis and interpretation; ZY, ZHL revised the manuscript.

Funding This study was supported by the National Natural Science Foundation of China (82070937 and 81870640) and the National Science Foundation for Young Scientists of China (82101097).

Availability of data and materials The datasets supporting the conclusions of this article are included within the article and its additional file.

Declarations

Conflict of interest All authors declare that they have no conflicts of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent The informed consent from each participant was obtained in the original study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Chong EW, Mehta JS (2016) High myopia and cataract surgery. Curr Opin Ophthalmol 27(1):45–50. https://doi. org/10.1097/icu.00000000000217
- Olsen T, Thim K, Corydon L (1991) Accuracy of the newer generation intraocular lens power calculation formulas in long and short eyes. J Cataract Refract Surg 17(2):187–193. https://doi.org/10.1016/s0886-3350(13) 80249-0
- Kane JX, Van Heerden A, Atik A, Petsoglou C (2016) Intraocular lens power formula accuracy: comparison of 7 formulas. J Cataract Refract Surg 42(10):1490–1500. https://doi.org/10.1016/j.jcrs.2016.07.021
- 4. Ji J, Liu Y, Zhang J, Wu X, Shao W, Ma B, Luo M (2021) Comparison of six methods for the intraocular lens

power calculation in high myopic eyes. Eur J Ophthalmol 31(1):96–102. https://doi.org/10.1177/1120672119889016

- Zhang Y, Liang XY, Liu S, Lee JW, Bhaskar S, Lam DS (2016) Accuracy of intraocular lens power calculation formulas for highly myopic eyes. J Ophthalmol 2016:1917268. https://doi.org/10.1155/2016/1917268
- Hill WE, Abulafia A, Wang L, Koch DD (2017) Pursuing perfection in IOL calculations. II. Measurement foibles: measurement errors, validation criteria, IOL constants, and lane length. J Cataract Refract Surg 43(7):869–70. http://doi.org/https://doi.org/10.1016/j.jcrs.2017.07.006
- Fayette RM, Cakiner-Egilmez T (2015) What factors affect intraocular lens power calculation? Insight 40(4):15–18
- Aristodemou P, Knox Cartwright NE, Sparrow JM, Johnston RL (2011) Formula choice: Hoffer Q, Holladay 1, or SRK/T and refractive outcomes in 8108 eyes after cataract surgery with biometry by partial coherence interferometry. J Cataract Refract Surg 37(1):63–71. https://doi.org/ 10.1016/j.jcrs.2010.07.032
- Cooke DL, Cooke TL (2016) Comparison of 9 intraocular lens power calculation formulas. J Cataract Refract Surg 42(8):1157–1164. https://doi.org/10.1016/j.jcrs.2016.06. 029
- Wang L, Shirayama M, Ma XJ, Kohnen T, Koch DD (2011) Optimizing intraocular lens power calculations in eyes with axial lengths above 25.0 mm. J Cataract Refract Surg 37(11):2018–2027. http://doi.org/https://doi.org/10. 1016/j.jcrs.2011.05.042
- Bang S, Edell E, Yu Q, Pratzer K, Stark W (2011) Accuracy of intraocular lens calculations using the IOLMaster in eyes with long axial length and a comparison of various formulas. Ophthalmology 118(3):503–506. https://doi.org/10.1016/j.ophtha.2010.07.008
- Chen C, Xu X, Miao Y, Zheng G, Sun Y, Xu X (2015) Accuracy of intraocular lens power formulas involving 148 eyes with long axial lengths: a retrospective chartreview study. J Ophthalmol 2015:976847. https://doi.org/ 10.1155/2015/976847
- Maclaren RE, Sagoo MS, Restori M, Allan BD (2005) Biometry accuracy using zero- and negative-powered intraocular lenses. J Cataract Refract Surg 31(2):280–290. https://doi.org/10.1016/j.jcrs.2004.04.054
- Roberts TV, Hodge C, Sutton G, Lawless M, Vision Eye Inst IOLO (2018) Comparison of Hill-radial basis function, Barrett Universal and current third generation formulas for the calculation of intraocular lens power during cataract surgery. Clin Exp Ophthalmol 46(3):240–246. https://doi.org/10.1111/ceo.13034
- Savini G, Taroni L, Hoffer KJ (2020) Recent developments in intraocular lens power calculation methodsupdate 2020. Ann Transl Med 8(22):1553. http://doi. org/https://doi.org/10.21037/atm-20-2290
- Melles RB, Holladay JT, Chang WJ (2018) Accuracy of intraocular lens calculation formulas. Ophthalmology 125(2):288–294. https://doi.org/10.1016/j.ophtha.2017. 08.027
- Hipolito-Fernandes D, Elisa Luis M, Gil P, Maduro V, Feijao J, Yeo TK, Voytsekhivskyy O, Alves N (2020) VRF-G, a new intraocular lens power calculation

formula: a 13-formulas comparison study. Clin Ophthalmol 14:4395–4402. https://doi.org/10.2147/opth.S290125

- Deshpande SN, Van Asselt AD, Tomini F, Armstrong N, Allen A, Noake C, Khan K, Severens JL, Kleijnen J, Westwood ME (2013) Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis. Health Technol Assess 17(40):1–138. https://doi.org/10.3310/ hta17400
- Wang Q, Jiang W, Lin T, Wu X, Lin H, Chen W (2018) Meta-analysis of accuracy of intraocular lens power calculation formulas in short eyes. Clin Exp Ophthalmol 46(4):356–363. https://doi.org/10.1111/ceo.13058
- Wang L, Cao D, Weikert MP, Koch DD (2019) Calculation of axial length using a single group refractive index versus using different refractive indices for each ocular segment: theoretical study and refractive outcomes. Ophthalmology 126(5):663–670. https://doi.org/10.1016/j. ophtha.2018.12.046
- Doshi D, Limdi P, Parekh N, Gohil N (2017) A comparative study to assess the predictability of different iol power calculation formulas in eyes of short and long axial length. J Clin Diagn Res 11(1):NC01–NC4. http://doi.org/https:// doi.org/10.7860/JCDR/2017/22095.9136
- 22. Rong X, He W, Zhu Q, Qian D, Lu Y, Zhu X (2019) Intraocular lens power calculation in eyes with extreme myopia: Comparison of Barrett Universal II, Haigis, and Olsen formulas. J Cataract Refract Surg 45(6):732–737. https://doi.org/10.1016/j.jcrs.2018.12.025
- Liu J, Wang L, Chai F, Han Y, Qian S, Koch DD, Weikert MP (2019) Comparison of intraocular lens power calculation formulas in Chinese eyes with axial myopia. J Cataract Refract Surg 45(6):725–731. https://doi.org/10.1016/j.jcrs.2019.01.018
- Kane JX, Van Heerden A, Atik A, Petsoglou C (2017) Accuracy of 3 new methods for intraocular lens power selection. J Cataract Refract Surg 43(3):333–339. https:// doi.org/10.1016/j.jcrs.2016.12.021
- Fuest M, Plange N, Kuerten D, Schellhase H, Mazinani BAE, Walter P, Kohnen S, Widder RA, Roessler G (2021) Intraocular lens power calculation for plus and minus lenses in high myopia using partial coherence interferometry. Int Ophthalmol. https://doi.org/10.1007/ s10792-020-01684-y
- Zhou D, Sun Z, Deng G (2019) Accuracy of the refractive prediction determined by intraocular lens power calculation formulas in high myopia. Indian J Ophthalmol 67(4):484–489. https://doi.org/10.4103/ijo.IJO_937_18
- Carmona-Gonzalez D, Castillo-Gomez A, Palomino-Bautista C, Romero-Dominguez M, Gutierrez-Moreno MA (2020) Comparison of the accuracy of 11 intraocular lens power calculation formulas. Eur J Ophthalmol. https://doi. org/10.1177/1120672120962030
- Zhang Z, Miao Y, Fang X, Luo Q, Wang Y (2018) Accuracy of the Haigis and SRK/T Formulas in Eyes Longer than 29.0 mm and the Influence of Central Corneal Keratometry Reading. Curr Eye Res 43(11):1316–21. http://doi.org/https://doi.org/10.1080/02713683.2018.1488265
- Idrobo-Robalino CA, Santaella G, Gutierrez AM (2019) T2 formula in a highly myopic population, comparison with other methods and description of an improved

approach for estimating corneal height. BMC Ophthalmol 19(1). http://doi.org/https://doi.org/10.1186/ s12886-019-1226-7

- Wan KH, Lam TCH, Yu MCV, Chan TCY (2019) Accuracy and precision of intraocular lens calculations using the new Hill-RBF Version 2.0 in eyes with high axial myopia. Am J Ophthalmol 205:66–73. https://doi.org/10.1016/j.ajo.2019.04.019
- Voytsekhivskyy OV (2018) Development and clinical accuracy of a new intraocular lens power formula (VRF) compared to other formulas. Am J Ophthalmol 185:56– 67. https://doi.org/10.1016/j.ajo.2017.10.020
- Wang Q, Jiang W, Lin T, Zhu Y, Chen C, Lin H, Chen W (2018) Accuracy of intraocular lens power calculation formulas in long eyes: a systematic review and meta-analysis. Clin Exp Ophthalmol 46(7):738–749. https://doi.org/10. 1111/ceo.13184
- Hoffer KJ, Aramberri J, Haigis W, Olsen T, Savini G, Shammas HJ, Bentow S (2015) Protocols for studies of intraocular lens formula accuracy. Am J Ophthalmol 160(3):403–5.e1. https://doi.org/10.1016/j.ajo.2015.05. 029
- Mcalinden C (2012) Corneal refractive surgery: past to present. Clin Exp Optom 95(4):386–398. https://doi.org/ 10.1111/j.1444-0938.2012.00761.x
- Alio JL, Abdelghany AA, Abdou AA, Maldonado MJ (2016) Cataract surgery on the previous corneal refractive surgery patient. Surv Ophthalmol 61(6):769–777. https:// doi.org/10.1016/j.survophthal.2016.07.001
- Savini G, Hoffer KJ (2018) Intraocular lens power calculation in eyes with previous corneal refractive surgery. Eye Vis 5:18. https://doi.org/10.1186/s40662-018-0110-5
- 37. Nejima R, Miyai T, Kataoka Y, Miyata K, Honbou M, Tokunaga T, Kawana K, Kiuchi T, Oshika T (2006) Prospective intrapatient comparison of 6.0-millimeter optic single-piece and 3-piece hydrophobic acrylic foldable intraocular lenses. Ophthalmology 113(4):585–590. http:// doi.org/https://doi.org/10.1016/j.ophtha.2005.10.064
- Lyle WA, Jin GJ (1996) Prospective evaluation of early visual and refractive effects with small clear corneal incision for cataract surgery. J Cataract Refract Surg 22(10):1456–1460. https://doi.org/10.1016/s0886-3350(96)80147-7
- Holladay JT, Prager TC, Chandler TY, Musgrove KH, Lewis JW, Ruiz RS (1988) A three-part system for refining intraocular lens power calculations. J Cataract Refract Surg 14(1):17–24. https://doi.org/10.1016/s0886-3350(88) 80059-2
- Hoffer KJ (1993) The Hoffer Q formula: a comparison of theoretic and regression formulas. J Cataract Refract Surg 19(6):700–712. https://doi.org/10.1016/s0886-3350(13) 80338-0

- Retzlaff JA, Sanders DR, Kraff MC (1990) Development of the SRK/T intraocular lens implant power calculation formula. J Cataract Refract Surg 16(3):333–340. https:// doi.org/10.1016/s0886-3350(13)80705-5
- 42. Haigis W, Lege B, Miller N, Schneider B (2000) Comparison of immersion ultrasound biometry and partial coherence interferometry for intraocular lens calculation according to Haigis. Graefes Arch Clin Exp Ophthalmol 238(9):765–773
- 43. De Bernardo M, Salerno G, Cornetta P, Rosa N (2018) Axial length shortening after cataract surgery: new approach to solve the question. Transl Vis Sci Technol 7(6):34. https://doi.org/10.1167/tvst.7.6.34
- Barrett GD (1993) An improved universal theoretical formula for intraocular lens power prediction. J Cataract Refract Surg 19(6):713–720. https://doi.org/10.1016/ s0886-3350(13)80339-2
- Olsen T, Hoffmann P (2014) C constant: new concept for ray tracing-assisted intraocular lens power calculation. J Cataract Refract Surg 40(5):764–773. https://doi.org/10. 1016/j.jcrs.2013.10.037
- Sheard RM, Smith GT, Cooke DL (2010) Improving the prediction accuracy of the SRK/T formula: the T2 formula. J Cataract Refract Surg 36(11):1829–1834. https:// doi.org/10.1016/j.jcrs.2010.05.031
- Ladas JG, Siddiqui AA, Devgan U, Jun AS (2015) A 3-D "Super Surface" combining modern intraocular lens formulas to generate a "Super Formula" and maximize accuracy. JAMA Ophthalmol 133(12):1431–1436. https://doi. org/10.1001/jamaophthalmol.2015.3832
- Savini G, Hoffer KJ, Balducci N, Barboni P, Schiano-Lomoriello D (2020) Comparison of formula accuracy for intraocular lens power calculation based on measurements by a swept-source optical coherence tomography optical biometer. J Cataract Refract Surg 46(1):27–33. https://doi. org/10.1016/j.jcrs.2019.08.044
- Connell BJ, Kane JX (2019) Comparison of the Kane formula with existing formulas for intraocular lens power selection. BMJ Open Ophthalmol 4(1):e000251. https:// doi.org/10.1136/bmjophth-2018-000251
- Wang L, Koch DD, Hill W, Abulafia A (2017) Pursuing perfection in intraocular lens calculations: III. Criteria for analyzing outcomes. J Cataract Refract Surg 43(8):999– 1002. http://doi.org/https://doi.org/10.1016/j.jcrs.2017.08. 003

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.